Saltar al contenido
Merck

Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

American journal of public health (2013-03-16)
Robert P Schwartz, Jan Gryczynski, Kevin E O'Grady, Joshua M Sharfstein, Gregory Warren, Yngvild Olsen, Shannon G Mitchell, Jerome H Jaffe
RESUMEN

We examined the association between the expansion of methadone and buprenorphine treatment and the prevalence of heroin overdose deaths in Baltimore, Maryland from 1995 to 2009. We conducted a longitudinal time series analysis of archival data using linear regression with the Newey-West method to correct SEs for heteroscedasticity and autocorrelation, adjusting for average heroin purity. Overdose deaths attributed to heroin ranged from a high of 312 in 1999 to a low of 106 in 2008. While mean heroin purity rose sharply (1995-1999), the increasing number of patients treated with methadone was not associated with a change in the number of overdose deaths, but starting in 2000 expansion of opioid agonist treatment was associated with a decline in overdose deaths. Adjusting for heroin purity and the number of methadone patients, there was a statistically significant inverse relationship between heroin overdose deaths and patients treated with buprenorphine (P = .002). Increased access to opioid agonist treatment was associated with a reduction in heroin overdose deaths. Implementing policies that support evidence-based medication treatment of opiate dependence may decrease heroin overdose deaths.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Buprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Buprenorphine hydrochloride
Supelco
Buprenorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Buprenorphine hydrochloride solution, analytical standard, for drug analysis